Vir Biotechnology to Highlight Immune-Based Innovations at Evercore ISI HealthCONx Conference

Vir Biotechnology Showcases Leadership and Innovation at Upcoming Conference

Vir Biotechnology Inc. prepares to highlight its ongoing commitment to advancing immune-based therapies at the 7th Annual Evercore ISI HealthCONx Conference, where CEO Marianne De Backer is set to engage in a fireside chat. Scheduled for December 3, 2023, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida, this event presents an opportunity for the company to discuss its innovative approaches in treating serious infectious diseases and cancer, as well as to connect with investors and stakeholders. Attendees and interested parties can access a live webcast of the discussion through the Investors section of Vir Biotechnology's website, ensuring that key insights from the session will be available for a month following the event.

Vir Biotechnology continues to focus on a robust clinical-stage portfolio, particularly in the development of therapies for chronic hepatitis delta and hepatitis B. The company is also deeply engaged in various programs targeting solid tumors, showcasing its dedication to addressing some of the most pressing health challenges faced by patients today. This multifaceted approach not only underscores Vir's commitment to tackling infectious diseases but also reflects its strategic vision for expanding its therapeutic impact in oncology. By leveraging its understanding of the immune system, Vir aims to create transformative solutions that significantly improve patient outcomes.

In addition to its clinical endeavors, Vir Biotechnology maintains a preclinical pipeline that addresses a broader spectrum of infectious diseases and oncologic conditions. This diverse array of research initiatives exemplifies the company's innovative spirit and its proactive stance in the biopharmaceutical industry. The firm emphasizes transparency and routinely updates investors through its website, reinforcing its commitment to open communication. As it prepares for the upcoming conference, Vir Biotechnology stands poised to share its advancements and future directions in the fight against serious health conditions, reflecting its mission to revolutionize healthcare through immune enhancement strategies.

Alongside its participation in the conference, Vir Biotechnology remains focused on its strategic goals and research initiatives. The company's innovative therapies aim to address unmet medical needs, ultimately striving to improve health outcomes for patients worldwide. As the biopharmaceutical landscape evolves, Vir's commitment to rigorous research and development is critical for advancing effective treatment options in the fight against infectious diseases and cancer.